OmniPod (Insulin Pump) and DexCom(Cont’ Blood Glucose Monitor) to Integrate

The OmniPod Insulin Pump will be wirelessly communicating with DexCom’s continuous blood glucose monitor, sometime soon with only one receiver.

Insulet the maker of the insulin pump technology with its OmniPod(R) Insulin Management System, and DexCom, Inc., a leading provider of continuous glucose monitoring systems for people with diabetes, announced they have signed a development agreement to integrate DexCom’s continuous glucose monitoring technology into the wireless, handheld OmniPod System Personal Diabetes Manager (PDM). In addition to programming the patient’s insulin delivery, the PDM with integrated DexCom technology will receive and display continuous glucose readings from DexCom’s wearable sensor transmitter. Patients using the integrated system will have access to real-time glucose values and trended glucose information, as well as alarms to warn patients if glucose levels are rising or falling.

The PDM with DexCom technology will combine the functionality of both systems’ handheld receivers into one single handheld wireless device, eliminating the need for a separate receiver. The PDM will be used to program the wearable OmniPod with insulin delivery instructions and will also receive and display continuous glucose readings directly from DexCom’s wearable sensor transmitter. The integrated system will provide patients with continuous information about glucose levels and allow patients to continuously track trends, enabling them to accurately anticipate excursions outside of normal glucose levels and to make appropriate treatment adjustments. Alarms on the PDM will immediately alert the patient when glucose levels are outside of the target range, allowing the patient the opportunity to intervene and prevent acute events. Development, clinical and regulatory efforts are expected to continue throughout 2008, with an anticipated product launch in mid-2009.

The agreement is non-exclusive and does not impact any of Insulet’s existing third party development agreements.

About The OmniPod Insulin Management System: Cleared by the FDA in 2005, the OmniPod Insulin Management System offers people living with insulin-dependent diabetes unprecedented freedom, comfort and ease in managing their diabetes. The System currently consists of two devices, the compact, lightweight OmniPod, which is worn discreetly beneath clothing and delivers precise, personalized doses of insulin based on instructions programmed wirelessly using its companion, the handheld, wireless Personal Diabetes Manager (PDM). The OmniPod features no tubing and virtually pain-free automated insertion. The PDM, which is very similar in look and feel to a personal digital assistant, features an integrated blood glucose meter, disease management software and integrated storage and display of all insulin delivery, blood glucose and carbohydrate records. www.myomnipod.com

About DexCom’s Continuous Glucose Monitoring Systems: Continuous glucose monitoring devices have the potential to dramatically improve a patient’s ability to tightly control their glucose levels and thereby reduce the risk of long-term diabetes-related complications. On May 31, 2007, the FDA approved DexCom’s second generation continuous glucose monitor, the SEVEN, and DexCom is now in national distribution with this device. DexCom’s recent approval allows for the use of the SEVEN by adults with diabetes for up to seven consecutive days to detect trends and track glucose patterns, to aid in the detection of hypoglycemia and hyperglycemia and to facilitate acute and long-term therapy adjustments. The SEVEN consists of three parts, a small subcutaneous sensor that measures glucose levels; a miniaturized transmitter that is water resistant and wirelessly sends glucose readings to a receiver; and a wireless receiver designed for easy viewing of 1-, 3- and 9-hour glucose trends and current glucose readings. www.dexcom.com

=====================================

FACT:

The U.S. has the highest rate of preventable deaths among 19 industrialized nations: according to a analysis published Thursday in the journal Health Affairs. The study examined preventable deaths in people younger than age 75 caused by 30 conditions that could have been treated with medical or surgical interventions, including tuberculosis, thyroid disease, appendicitis, tetanus infections, abdominal hernia, colon cancer, measles and epilepsy. The analysis also included deaths in people younger than age 50 caused by leukemia, cervical cancer and diabetes. The report focused on people whose lives would have been extended with widely available medical treatment. According to the study, if the rate of preventable deaths in the U.S. improved to the average of the top three countries — France, Japan and Australia — 101,000 fewer U.S. residents would die annually. Of the countries examined, the U.S. is the only one without universal health care coverage.